Clarivate (CLVT) Q2 2026 Earnings Call Transcript
Clarivate reports Q2 2026 revenue decline due to divestitures, highlights strategic shift to subscription models, and outlines AI-driven growth initiatives.Summary
Clarivate (CLVT) reported Q2 2026 revenues of $587.3 million, a 5.5% decrease primarily due to inorganic divestitures and lower organic transactional revenues. Adjusted EBITDA stood at $247.2 million with a 42.1% margin, driven by cost efficiencies. The company announced the divestiture of its Life Sciences & Healthcare segment to Altaris, aiming to increase pro forma recurring revenue mix to 92% and reduce debt by $900 million. Key AI initiatives include Web of Science Research Intelligence, Nexus Connect, and IP-1, which leverage proprietary datasets and agentic AI capabilities. Management emphasized strategic portfolio rationalization, focusing on core academic and intellectual property markets. Michael Easton was appointed CFO, succeeding Jonathan Collins. Full-year guidance anticipates revenue between $2.30B-$2.42B, adjusted EBITDA of $980M-$1.04B, and free cash flow of $365M-$435M, with debt reduction as a priority.
(Source：Fool)